Logo image of IVA

INVENTIVA SA - ADR (IVA) Stock Price, Quote, News and Overview

NASDAQ:IVA - Nasdaq - US46124U1079 - ADR - Currency: USD

3.22  -0.12 (-3.74%)

IVA Quote, Performance and Key Statistics

INVENTIVA SA - ADR

NASDAQ:IVA (8/1/2025, 8:00:02 PM)

3.22

-0.12 (-3.74%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.05
52 Week Low1.53
Market Cap447.85M
Shares139.08M
Float115.90M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-21 2025-11-21
IPO02-15 2017-02-15


IVA short term performance overview.The bars show the price performance of IVA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

IVA long term performance overview.The bars show the price performance of IVA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of IVA is 3.22 USD. In the past month the price increased by 6.98%. In the past year, price increased by 41.85%.

INVENTIVA SA - ADR / IVA Daily stock chart

IVA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 344.84B
AMGN AMGEN INC 14.3 159.64B
GILD GILEAD SCIENCES INC 14.62 140.79B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.67B
REGN REGENERON PHARMACEUTICALS 12.25 60.34B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 52.39B
ARGX ARGENX SE - ADR 72.69 41.24B
ONC BEONE MEDICINES LTD-ADR 7.68 32.36B
BNTX BIONTECH SE-ADR N/A 25.80B
INSM INSMED INC N/A 20.62B
SMMT SUMMIT THERAPEUTICS INC N/A 20.10B
BIIB BIOGEN INC 8.24 19.33B

About IVA

Company Profile

IVA logo image Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 109 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Company Info

INVENTIVA SA - ADR

50 rue de Dijon, Daix

Daix OCCITANIE 21121 FR

CEO: Frederic Cren

Employees: 116

IVA Company Website

IVA Investor Relations

Phone: 33380447500

INVENTIVA SA - ADR / IVA FAQ

What is the stock price of INVENTIVA SA - ADR today?

The current stock price of IVA is 3.22 USD. The price decreased by -3.74% in the last trading session.


What is the ticker symbol for INVENTIVA SA - ADR stock?

The exchange symbol of INVENTIVA SA - ADR is IVA and it is listed on the Nasdaq exchange.


On which exchange is IVA stock listed?

IVA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INVENTIVA SA - ADR stock?

11 analysts have analysed IVA and the average price target is 10.86 USD. This implies a price increase of 237.25% is expected in the next year compared to the current price of 3.22. Check the INVENTIVA SA - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INVENTIVA SA - ADR worth?

INVENTIVA SA - ADR (IVA) has a market capitalization of 447.85M USD. This makes IVA a Small Cap stock.


How many employees does INVENTIVA SA - ADR have?

INVENTIVA SA - ADR (IVA) currently has 116 employees.


What are the support and resistance levels for INVENTIVA SA - ADR (IVA) stock?

INVENTIVA SA - ADR (IVA) has a support level at 3.14 and a resistance level at 3.24. Check the full technical report for a detailed analysis of IVA support and resistance levels.


Is INVENTIVA SA - ADR (IVA) expected to grow?

The Revenue of INVENTIVA SA - ADR (IVA) is expected to grow by 193.39% in the next year. Check the estimates tab for more information on the IVA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INVENTIVA SA - ADR (IVA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INVENTIVA SA - ADR (IVA) stock pay dividends?

IVA does not pay a dividend.


When does INVENTIVA SA - ADR (IVA) report earnings?

INVENTIVA SA - ADR (IVA) will report earnings on 2025-11-21.


What is the Price/Earnings (PE) ratio of INVENTIVA SA - ADR (IVA)?

INVENTIVA SA - ADR (IVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.63).


What is the Short Interest ratio of INVENTIVA SA - ADR (IVA) stock?

The outstanding short interest for INVENTIVA SA - ADR (IVA) is 0.03% of its float. Check the ownership tab for more information on the IVA short interest.


IVA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to IVA. When comparing the yearly performance of all stocks, IVA is one of the better performing stocks in the market, outperforming 79.96% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IVA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to IVA. IVA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IVA Financial Highlights

Over the last trailing twelve months IVA reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS decreased by -20.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -154.84%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-76.47%
Sales Q2Q%-41.21%
EPS 1Y (TTM)-20.47%
Revenue 1Y (TTM)-47.37%

IVA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to IVA. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 56.03% and a revenue growth 193.39% for IVA


Ownership
Inst Owners54.98%
Ins Owners6.82%
Short Float %0.03%
Short Ratio1.79
Analysts
Analysts87.27
Price Target10.86 (237.27%)
EPS Next Y56.03%
Revenue Next Year193.39%